Efficacy of Pfizer-BioNTech in SARS-CoV-2 Delta cluster

Efficacy of Pfizer-BioNTech in SARS-CoV-2 Delta cluster

ABSTRACT: Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) sublineage B.1.617.2 or Delta, a variant that began circulating in India and is becoming dominant in the USA, has been responsible for significant morbidity and mortality. In May 2021, the Delta variant was upgraded to a variant...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Hannah E. Landsberg, MSN, MPH, Jacquelyn Turcinovic, B.S., Madison Sullivan, MPH, John H. Connor, Ph.D., Davidson H. Hamer, MD, Judy T. Platt, MD
Formato: article
Lenguaje:EN
Publicado: Elsevier 2022
Materias:
COVID-19
Sequencing
Delta variant
Variant of concern
PCR testing
Contact tracing
Infectious and parasitic diseases
RC109-216
Acceso en línea:https://doaj.org/article/52bd5f1be98c4a7b8d31ec631ce2ec32
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/52bd5f1be98c4a7b8d31ec631ce2ec32

Ejemplares similares